nodes	percent_of_prediction	percent_of_DWPC	metapath
Tasosartan—CYP3A4—Pilocarpine—glaucoma	0.148	0.236	CbGbCtD
Tasosartan—CYP3A4—Brinzolamide—glaucoma	0.116	0.185	CbGbCtD
Tasosartan—CYP3A4—Dorzolamide—glaucoma	0.112	0.178	CbGbCtD
Tasosartan—CYP3A4—Methazolamide—glaucoma	0.0997	0.159	CbGbCtD
Tasosartan—CYP3A4—Acetazolamide—glaucoma	0.0797	0.127	CbGbCtD
Tasosartan—AGTR2—ACE Inhibitor Pathway—MAS1—glaucoma	0.0786	0.211	CbGpPWpGaD
Tasosartan—CYP3A4—Clonidine—glaucoma	0.0721	0.115	CbGbCtD
Tasosartan—AGTR2—ACE Inhibitor Pathway—ACE2—glaucoma	0.0596	0.16	CbGpPWpGaD
Tasosartan—AGTR1—ACE Inhibitor Pathway—MAS1—glaucoma	0.0256	0.0687	CbGpPWpGaD
Tasosartan—AGTR1—ACE Inhibitor Pathway—ACE2—glaucoma	0.0194	0.052	CbGpPWpGaD
Tasosartan—AGTR2—ACE Inhibitor Pathway—NOS3—glaucoma	0.0131	0.0352	CbGpPWpGaD
Tasosartan—AGTR2—GPCRs, Class A Rhodopsin-like—MAS1—glaucoma	0.00893	0.0239	CbGpPWpGaD
Tasosartan—AGTR2—GPCRs, Class A Rhodopsin-like—OPN4—glaucoma	0.00816	0.0219	CbGpPWpGaD
Tasosartan—AGTR2—GPCRs, Class A Rhodopsin-like—PTGFR—glaucoma	0.00735	0.0197	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—OPN4—glaucoma	0.00699	0.0187	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—PTGFR—glaucoma	0.0063	0.0169	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—OPN4—glaucoma	0.00533	0.0143	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—PTGFR—glaucoma	0.0048	0.0129	CbGpPWpGaD
Tasosartan—AGTR1—ACE Inhibitor Pathway—NOS3—glaucoma	0.00427	0.0115	CbGpPWpGaD
Tasosartan—AGTR1—G alpha (q) signalling events—OPN4—glaucoma	0.00344	0.00922	CbGpPWpGaD
Tasosartan—AGTR2—Peptide ligand-binding receptors—EDN1—glaucoma	0.00312	0.00837	CbGpPWpGaD
Tasosartan—AGTR1—G alpha (q) signalling events—PTGFR—glaucoma	0.0031	0.00831	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—OPN4—glaucoma	0.00308	0.00825	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—OPN4—glaucoma	0.00301	0.00807	CbGpPWpGaD
Tasosartan—AGTR1—GPCRs, Class A Rhodopsin-like—MAS1—glaucoma	0.00291	0.0078	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PTGFR—glaucoma	0.00277	0.00743	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—OPN4—glaucoma	0.00273	0.00733	CbGpPWpGaD
Tasosartan—AGTR2—Peptide ligand-binding receptors—C3—glaucoma	0.00273	0.00731	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—PTGFR—glaucoma	0.00271	0.00726	CbGpPWpGaD
Tasosartan—AGTR1—GPCRs, Class A Rhodopsin-like—OPN4—glaucoma	0.00266	0.00713	CbGpPWpGaD
Tasosartan—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—glaucoma	0.00261	0.00699	CbGpPWpGaD
Tasosartan—CYP3A4—Aflatoxin B1 metabolism—GSTM1—glaucoma	0.00255	0.00683	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—PTGFR—glaucoma	0.00246	0.0066	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—SMO—glaucoma	0.00242	0.00648	CbGpPWpGaD
Tasosartan—AGTR1—GPCRs, Class A Rhodopsin-like—PTGFR—glaucoma	0.0024	0.00642	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—LRP12—glaucoma	0.00233	0.00624	CbGpPWpGaD
Tasosartan—AGTR2—G alpha (i) signalling events—C3—glaucoma	0.0023	0.00617	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—OPN4—glaucoma	0.00228	0.00611	CbGpPWpGaD
Tasosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—FN1—glaucoma	0.00227	0.00608	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—EDN1—glaucoma	0.00209	0.00561	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—PTGFR—glaucoma	0.00205	0.0055	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—IL1A—glaucoma	0.00204	0.00547	CbGpPWpGaD
Tasosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MMP2—glaucoma	0.00192	0.00516	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—C3—glaucoma	0.00183	0.0049	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—FAS—glaucoma	0.00182	0.00487	CbGpPWpGaD
Tasosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—NOS3—glaucoma	0.0018	0.00483	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—C3—glaucoma	0.00179	0.00481	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—OPN4—glaucoma	0.00174	0.00465	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—OPN4—glaucoma	0.00161	0.00433	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—EDN1—glaucoma	0.00159	0.00427	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—PTGFR—glaucoma	0.00156	0.00419	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—HEYL—glaucoma	0.0015	0.00402	CbGpPWpGaD
Tasosartan—CYP3A4—Estrogen metabolism—CYP1B1—glaucoma	0.0015	0.00402	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PTGFR—glaucoma	0.00145	0.0039	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—C3—glaucoma	0.00139	0.00373	CbGpPWpGaD
Tasosartan—CYP3A4—Tamoxifen metabolism—CYP1B1—glaucoma	0.00132	0.00355	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—SMO—glaucoma	0.00124	0.00333	CbGpPWpGaD
Tasosartan—CYP3A4—Estrogen metabolism—GSTM1—glaucoma	0.0012	0.00321	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—RPTOR—glaucoma	0.00114	0.00305	CbGpPWpGaD
Tasosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—glaucoma	0.00111	0.00298	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—NCK2—glaucoma	0.0011	0.00295	CbGpPWpGaD
Tasosartan—AGTR1—G alpha (q) signalling events—EDN1—glaucoma	0.00103	0.00276	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—EDN1—glaucoma	0.00102	0.00273	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—OPN4—glaucoma	0.000981	0.00263	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—HDAC9—glaucoma	0.000937	0.00251	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—glaucoma	0.000921	0.00247	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—EDN1—glaucoma	0.000901	0.00241	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—VEGFA—glaucoma	0.000901	0.00241	CbGpPWpGaD
Tasosartan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—glaucoma	0.000901	0.00241	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—OPN4—glaucoma	0.000891	0.00239	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—C3—glaucoma	0.000888	0.00238	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—PTGFR—glaucoma	0.000883	0.00237	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—EDN1—glaucoma	0.000818	0.00219	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—PTGFR—glaucoma	0.000802	0.00215	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—SMO—glaucoma	0.000788	0.00211	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—C3—glaucoma	0.000787	0.00211	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—TNF—glaucoma	0.000772	0.00207	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—LRP12—glaucoma	0.000759	0.00203	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—SMO—glaucoma	0.000733	0.00196	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—C3—glaucoma	0.000715	0.00192	CbGpPWpGaD
Tasosartan—CYP3A4—Tryptophan metabolism—CYP1B1—glaucoma	0.000707	0.0019	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—EDN1—glaucoma	0.000682	0.00183	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—NTRK2—glaucoma	0.00067	0.0018	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—C3—glaucoma	0.000596	0.0016	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—NGFR—glaucoma	0.000575	0.00154	CbGpPWpGaD
Tasosartan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—glaucoma	0.000572	0.00153	CbGpPWpGaD
Tasosartan—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—glaucoma	0.000564	0.00151	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—NTRK1—glaucoma	0.000547	0.00147	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—OPN4—glaucoma	0.000526	0.00141	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—EDN1—glaucoma	0.000519	0.00139	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CDKN2B—glaucoma	0.000504	0.00135	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—HEYL—glaucoma	0.000489	0.00131	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—EDN1—glaucoma	0.000483	0.0013	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PTGFR—glaucoma	0.000474	0.00127	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	0.000464	0.00124	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—C3—glaucoma	0.000454	0.00122	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—NGF—glaucoma	0.000444	0.00119	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—C3—glaucoma	0.000422	0.00113	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—SMO—glaucoma	0.000404	0.00108	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—APOE—glaucoma	0.000393	0.00105	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CAV1—glaucoma	0.000389	0.00104	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—RPTOR—glaucoma	0.000371	0.000994	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—FN1—glaucoma	0.000371	0.000994	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—BAD—glaucoma	0.000366	0.000982	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NCK2—glaucoma	0.000359	0.000962	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—GSTT1—glaucoma	0.000309	0.000828	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—HDAC9—glaucoma	0.000305	0.000818	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—NOS3—glaucoma	0.000294	0.000789	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—EDN1—glaucoma	0.000294	0.000787	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—EDN1—glaucoma	0.000267	0.000715	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—C3—glaucoma	0.000256	0.000687	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CDKN1B—glaucoma	0.000255	0.000684	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—CYP1B1—glaucoma	0.000246	0.00066	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—CYP1B1—glaucoma	0.000243	0.000651	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—SMO—glaucoma	0.000239	0.00064	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—MMP9—glaucoma	0.000236	0.000633	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—C3—glaucoma	0.000233	0.000624	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NTRK2—glaucoma	0.000218	0.000586	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CA5A—glaucoma	0.000217	0.000581	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—NARFL—glaucoma	0.000217	0.000581	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—VEGFA—glaucoma	0.000212	0.000569	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—GSTM1—glaucoma	0.000197	0.000528	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—GSTM1—glaucoma	0.000194	0.00052	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NGFR—glaucoma	0.000187	0.000502	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NTRK1—glaucoma	0.000178	0.000477	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CDKN2B—glaucoma	0.000164	0.00044	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—TP53—glaucoma	0.00016	0.00043	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—EDN1—glaucoma	0.000157	0.000422	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NGF—glaucoma	0.000145	0.000388	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—C3—glaucoma	0.000138	0.000369	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—APOE—glaucoma	0.000128	0.000343	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CAV1—glaucoma	0.000127	0.00034	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—FN1—glaucoma	0.000121	0.000324	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—BAD—glaucoma	0.000119	0.00032	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CA1—glaucoma	0.000106	0.000284	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CTSA—glaucoma	0.000102	0.000275	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CA2—glaucoma	9.67e-05	0.000259	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NOS3—glaucoma	9.6e-05	0.000257	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CDKN1B—glaucoma	8.31e-05	0.000223	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—MMP9—glaucoma	7.7e-05	0.000206	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—VEGFA—glaucoma	6.91e-05	0.000185	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—TXN—glaucoma	6.82e-05	0.000183	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GSTT1—glaucoma	5.28e-05	0.000142	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—TP53—glaucoma	5.22e-05	0.00014	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP1B1—glaucoma	4.21e-05	0.000113	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ABCA1—glaucoma	4.21e-05	0.000113	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GSTM1—glaucoma	3.37e-05	9.02e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—MTHFR—glaucoma	2.98e-05	7.97e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—APOE—glaucoma	2.77e-05	7.42e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CAV1—glaucoma	2.74e-05	7.36e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—NOS3—glaucoma	2.07e-05	5.56e-05	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PTGS2—glaucoma	1.9e-05	5.09e-05	CbGpPWpGaD
